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BK polyomavirus (BKPyV) is a DNA virus belonging to the Polyomaviridae family. BKPyV is 
considered ubiquitous among the population, and primary infection usually occurs during 
early childhood. This primary infection is usually asymptomatic, following which the virus 
establishes a lifelong persistent infection mainly on epithelial cells of the urinary tract and the 
kidney. In immunocompetent individuals the virus remains clinically silent throughout the life 
of the host. Immunosuppression, however, can lead to reactivation of the latent infection. In 
such conditions, one of the major clinical complications of BKPyV reactivation is 
polyomavirus-associated nephropathy (PyVAN) in kidney transplant recipients. The 
development of more potent immunosuppressant drugs has increased the incidence rate of 
PyVAN in these patients and to date, because a specific and safe antiviral drug against 
BKPyV is still lacking, the mainstay approach to avoid PyVAN development and the 
possibility of graft loss is to reduce the immunosuppressive treatment. In this context, the 
development and search for antiviral drugs that can efficiently stop BKPyV replication has 
become of great clinical interest.  
This project focused on studying the efficacy of two drugs - NA-17 and TN-18 - against 
BKPyV replication in hTERT immortalized human renal proximal tubular epithelial cells 
(RPTEC/TERT1), an immortalized cell line of the major target cells of the virus in vivo. 
Results showed an inhibition of BKPyV infection with both NA-17 and TN-18, having been 
estimated effective concentration 50% (EC50) values of 190 μM and 682 μM, respectively. 
Treatment of BKPyV-infected RPTEC/TERT1 with the highest concentrations tested for both 
drugs was responsible for a decrease of the extracellular BKPyV DNA load, that although 
discrete, corresponded also with an inhibition of the release of infectious progeny. Overall 
our results show a moderate antiviral effect against BKPyV for both drugs, making us believe 
that they would have only a limited effect on treating this infection in vivo. Further research in 
this area is needed to develop an efficient treatment against BKPyV infection and to improve 
disease outcomes in kidney transplant recipients that develop PyVAN as a result of BKPyV 
infection reactivation. 
 





O poliomavírus BK é um vírus de DNA pertencente à família Polyomaviridae. A infeção 
primária é normalmente assintomática, após a qual o vírus estabelece uma infeção 
persistente maioritariamente nas células epiteliais do trato urinário e do rim. Em indivíduos 
imunocompetentes o vírus permanece clinicamente silencioso durante toda a vida do 
hospedeiro. No entanto, a imunossupressão pode conduzir à reativação do vírus latente, 
sendo uma das principais complicações desta reativação a nefropatia associada a 
poliomavírus em transplantados renais. O desenvolvimento de imunossupressores cada vez 
mais potentes tem aumentado a incidência da nefropatia nestes doentes e atualmente, não 
existindo nenhum antiviral que possa ser utilizado de forma eficaz e segura contra este 
vírus, a abordagem clínica consiste na redução do tratamento imunossupressor de modo a 
prevenir o desenvolvimento da nefropatia. Neste contexto, o desenvolvimento e a procura de 
antivirais que consigam eficazmente impedir a replicação do poliomavírus BK têm assumido 
um grande interesse clínico.  
O principal objetivo deste projeto consistiu no estudo da eficácia de dois compostos - NA-17 
e TN-18 - contra a replicação do poliomavírus BK em células epiteliais tubulares proximais 
renais imortalizadas com hTERT (RPTEC/TERT1), uma linha celular imortalizada de um dos 
maiores alvos celulares do vírus in vivo. Os resultados mostraram uma inibição da infeção 
pelo poliomavírus BK, tendo sido estimadas as concentrações responsáveis por uma 
inibição de 50% da infeção de 190 μM e 682 μM para o NA-17 e o TN-18, respetivamente. O 
tratamento com as concentrações mais elevadas testadas para ambos os compostos foi 
responsável por uma redução da carga extracelular de DNA viral, assim como na redução 
de libertação de novas partículas virais infeciosas. De um modo geral, os resultados 
mostram um efeito antiviral moderado de ambos os compostos contra o poliomavírus BK, 
mostrando que teriam um efeito limitado no tratamento desta infeção in vivo. A continuação 
da investigação nesta área é necessária para o desenvolvimento de um tratamento eficaz da 
infeção pelo poliomavírus BK e para a melhoria do prognóstico nos transplantados renais 
que desenvolvem nefropatia como resultado da reativação desta infeção.  
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BKPyV BK polyomavirus 
c/mL copies/mL 
CC50 cytotoxic concentration 50% 
CC90 cytotoxic concentration 90% 
CI confidence intervals 
CSK cytoskeletal buffer 
DMEM Dulbecco's modified Eagle medium 
DMSO dimethyl sulfoxide 
dpi days post-infection 
hpi hours post-infection 
dsDNA double-stranded DNA 
EC50 effective concentration 50%  
EC90 effective concentration 90% 
ER endoplasmic reticulum 
ERAD ER-associated degradation 
FBS  fetal bovine serum 
FAM  6-carboxyfluorescein 
GA-100 gentamicin and amphotericin B 
HEK293 human embryonic kidney 293 
HLA human leukocyte antigen 
hTERT human telomerase reverse transcriptase  
IARC International Agency for Research on Cancer 
IVIG intravenous immunoglobulin 
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JCPyV JC polyomavirus  
kbp kilobase pairs 
MCPyV Merkell cell polyomavirus 
miRNA microRNA 
MOI multiplicity of infection 
MPyV mouse polyomavirus 
mRNA messenger RNA 
mTOR mammalian target of rapamycin 
NAb neutralizing antibodies 
NCCR non-coding control region 
NLS nuclear localization sequences 
ORI origin of replication 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PFA paraformaldehyde 
pre-miRNA precursor-miRNA 
PyVAN polyomavirus-associated nephropathy 
qPCR quantitative real-time PCR 
REGM renal epithelial growth medium 
RPTEC human renal proximal tubular epithelial cells 
RPTEC/TERT1 hTERT immortalized RPTEC 
RT-qPCR reverse transcription qPCR 
SI selectivity index 
SV40 simian virus 40 
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TAg large tumor antigen 
tAg small tumor antigen 
TCID50 50% tissue culture infectious dose 
truncTAg truncated TAg 
TSPyV Trichodysplasia spinulosa-associated polyomavirus 
VLP virus-like particle 
 
9 
Table of Contents 
Abstract ................................................................................................................................. 3 
Resumo ................................................................................................................................. 4 
Acknowledgments ................................................................................................................. 5 
List of abbreviations .............................................................................................................. 6 
Table of Contents .................................................................................................................. 9 
List of Figures .......................................................................................................................10 
List of Tables ........................................................................................................................10 
1. Introduction ......................................................................................................................11 
1.1. BK polyomavirus ........................................................................................................11 
1.1.1. BKPyV virion ........................................................................................................12 
1.1.2. BKPyV genome ....................................................................................................13 
1.1.2.1. Genotypes and variants .................................................................................14 
1.1.3. BKPyV replication cycle .......................................................................................15 
1.2. Primary infection, latency and reactivation .................................................................17 
1.3. Polyomavirus-associated nephropathy .......................................................................18 
1.3.1. Early screening and diagnosis..............................................................................19 
1.3.2. Therapeutic approaches.......................................................................................20 
1.4. Model systems for the study of BKPyV infection .........................................................24 
2. Aims of this study .............................................................................................................26 
3. Materials and Methods .....................................................................................................27 
3.1. Cell culture .................................................................................................................27 
3.2. Virus ...........................................................................................................................27 
3.2.1. Virus stock production ..........................................................................................27 
3.2.1. Virus stock titration ...............................................................................................27 
3.3. Infection and drug treatment .......................................................................................28 
3.4. Immunofluorescence staining, microscopy, and digital image processing ..................28 
3.5. Extracellular BKPyV DNA load ...................................................................................29 
  10 
3.6. Release of infectious progeny ....................................................................................30 
3.7. Calculation of the effective concentrations 50% .........................................................30 
4. Results .............................................................................................................................31 
4.1. Effect of NA-17 and TN-18 on BKPyV infection on Vero cells .....................................31 
4.1.1. Inhibition of BKPyV infection ................................................................................31 
4.2. Effect of NA-17 and TN-18 on BKPyV infection on RPTEC/TERT1 ............................32 
4.2.1. Inhibition of BKPyV infection ................................................................................32 
4.2.2. Effect on BKPyV genome replication ....................................................................34 
4.2.3. Effect on the release of infectious progeny ...........................................................35 
5. Discussion ........................................................................................................................37 
6. Conclusions and Future Outlooks .....................................................................................41 
7. References .......................................................................................................................44 
 
List of Figures 
Figure 1. Cryo-electron microscopy structure of BKPyV virions. ........................................... 12 
Figure 2. Structure of BKPyV genome. ................................................................................. 13 
Figure 3. Schematic representation of BKPyV replication cycle. ........................................... 15 
Figure 4. Description of the QuantIF macro. ......................................................................... 29 
Figure 5. Effect of increasing concentrations of NA-17 and TN-18 on the inhibition of BKPyV 
infection on Vero cells. ......................................................................................................... 32 
Figure 6. Effect of increasing concentrations of NA-17 and TN-18 on the inhibition of BKPyV 
infection on RPTEC/TERT1. ................................................................................................. 33 
Figure 7. Effect of increasing concentrations of NA-17 and TN-18 on BKPyV DNA load.   ... 34 
Figure 8. Effect of increasing concentrations of NA-17 and TN-18 on the release of infectious 
progeny. ............................................................................................................................... 35 
 
List of Tables 
Table 1. Calculated EC50 values for NA-17 and TN-18 tested on RPTEC/TERT1 ................. 34 
 
Evaluation of antiviral drugs against BK polyomavirus 
Carolina Conceição   11 
1. Introduction 
1.1. BK polyomavirus 
BK polyomavirus (BKPyV) is a member of the Polyomaviridae family of non-enveloped, small 
viruses, with 40 to 45 nm in diameter, and circular double-stranded DNA (dsDNA) genomes 
comprising approximately 5 kilobase pairs (kbp) (1). The polyomavirus family was first 
named after its founding member, the mouse polyomavirus (MPyV), which was found to 
cause tumors in mice (polyoma meaning “many tumors”) (2). This family has now more than 
eighty different viruses divided in four genera, each of them having a specific host range, 
including mammals, birds and fish (1).  
Polyomaviruses with the ability to infect humans were first described in 1971. BKPyV was 
first isolated by inoculating Vero cells with urine samples of a patient who exhibited chronic 
pyelonephritis and advanced renal failure, and that for those reasons had undergone kidney 
transplant (3). In the same issue of The Lancet, independently, it was reported the isolation 
of JC polyomavirus (JCPyV) from brain tissue of a patient with Hodgkin’s disease who had 
developed progressive multifocal leukoencephalopathy (4). These viruses, both named after 
the patients’ initials, were the first two human polyomaviruses to be isolated. After these, 
numerous human polyomaviruses have been described, and to date, there are 13 
polyomaviruses that are known to infect humans (1). 
Human polyomaviruses are considered ubiquitous among the population, but primary 
infections with these viruses are generally not associated with significant clinical symptoms 
or disease. Immunosuppression, however, can lead to reactivation of the latent infection, and 
in such conditions there are four different human polyomaviruses that have been associated 
with human diseases (1). BKPyV is one of these viruses, and major complications, when 
reactivated, include polyomavirus-associated nephropathy (PyVAN) and hemorrhagic cystitis 
in kidney and hematopoietic stem cell transplant recipients, respectively (5). Additionally, 
JCPyV is associated with progressive multifocal leukoencephalopathy (6), Trichodysplasia 
spinulosa-associated polyomavirus (TSPyV) with trichodysplasia spinulosa (7), and Merkell 
cell polyomavirus (MCPyV) with Merkel cell carcinoma (8). Concerning their oncogenic 
potential, current evidence only supports the role of MCPyV as carcinogenic to humans, 
being classified by the International Agency for Research on Cancer (IARC) as “probably 
carcinogenic to humans” (group 2A). Other human polyomaviruses have already been found 
in tumors and efforts have been made to clarify the link between infection with these viruses 
and tumor development. However, their role in human cancer is not completely understood 
and BKPyV and JCPyV are only classified as “possibly carcinogenic to humans” (group 2B) 
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(9,10). As for the other human polyomaviruses, a relation between infection and disease 
development as not yet been established (10).  
BK virus shares approximately 75% genome homology with JCPyV and also 70% homology 
with simian virus 40 (SV40) (11), a virus first isolated from rhesus monkey kidney cells that 
had been used for poliovirus vaccine production (12). 
 
1.1.1. BKPyV virion 
BKPyV virions are non-enveloped, with approximately 45 nm in diameter. The viral capsid, 
with an icosahedral symmetry, is composed of three structural proteins, the major capsid 
protein VP1, and the two minor capsid proteins VP2 and VP3. On the outer surface of the 
capsid, 360 copies of VP1 form 72 pentamers arranged in a T=7d icosahedral structure (13) 
(Figure 1). The pentamers are linked between them through the C-terminal arm of VP1, and 
are further stabilized by disulfide bonds and calcium cations (14). Each of these pentamers is 




Figure 1. Cryo-electron microscopy structure of BKPyV virions. (A) View of a 40-Å thick slab through the 
unsharpened/unmasked virion map shown at a contour level of 0.0034. Pyramidal density below each VP1 
penton and two shells of electron density adjacent to the inner capsid layer can be seen. The density within 6 Å of 
the fitted coordinates for SV40 VP1 is colored gray. The remaining density is colored in a radial color scheme. 
Densities for VP2 and VP3 are colored blue and green, and for packaged dsDNA yellow and pink. (B) Enlarged 
view of the pyramidal density beneath a single VP1 penton of the virion shown at a contour level of 0.0032. 
Strands of dsDNA wrapped around a human histone octamer (PDB: 1AOI) are shown, indicating that the two 
shells of density have a comparable spacing. Discrete connective density between the pyramidal density and 
internal shells is also apparent. (Adapted from Hurdiss, et al., 2016) 
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The capsid encloses the viral genome, a single circular dsDNA molecule, packed with the 
cellular histones H2A, H2B, H3 and H4 under the form of a minichromossome containing 
around 20 nucleosomes (13). 
 
1.1.2. BKPyV genome 
The BKPyV genome comprises about 5 kbp and it is divided into two transcriptional regions, 
the early and the late coding regions (referring to the phase of the infection in which each of 
them is transcribed), separated by the non-coding control region (NCCR), a highly variable 
region (1) (Figure 2).  
 
Figure 2. Structure of BKPyV genome. The BKPyV genome is a closed circular, double-stranded DNA (dsDNA) 
molecule comprising approximately 5 kbp. It is divided into two transcriptional regions, the early and the late 
coding regions, separated by the non-coding control region (NCCR). Transcription of both early and late coding 
regions proceeds in a bidirectional way from the origin of replication (ORI) within the NCCR. The early coding 
region encodes the large tumor antigen (TAg), the small tumor antigen (tAg) and the truncated TAg (truncTAg). 
The late coding region encodes the structural proteins (VP1, VP2, and VP3) as well as the agnoprotein. The late 
coding region also encodes for two microRNA (miRNA), 5p-miRNA and 3p-miRNA, produced after processing of 
a common precursor-miRNA (pre-miRNA). (Adapted from Helle, et al., 2017) 
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Within the NCCR is located the origin of replication (ORI), from where the replication 
proceeds in a bidirectional way, and also promoters and regulatory regions of early and late 
gene transcription. The early region encodes for three proteins, the large tumor antigen 
(TAg), the small tumor antigen (tAg) and the truncated TAg (truncTAg), that are expressed 
prior to DNA replication. The late region is only transcribed after the onset of DNA replication, 
and encodes for the structural proteins VP1, VP2 and VP3, as well as the agnoprotein 
(15,16). The late coding region also encodes for two microRNA (miRNA), referred to as 5p-
miRNA and 3p-miRNA, produced after processing of a common precursor-miRNA (pre-
miRNA) perfectly complementary to the 3′ end of the TAg messenger RNA (mRNA) (17). 
 
1.1.2.1. Genotypes and variants 
BKPyV can be divided into four genotypes (I to IV) due to variations on the genomic region 
coding for VP1 (18). Genotype I is further divided into the subgroups Ia, Ib1, Ib2, and Ic (19), 
and genotype IV into subgroups IVa1, IVa2, IVb1, IVb2, IVc1, and IVc2 (20). The most 
prevalent is genotype I, distributed worldwide, followed by genotype IV which is found in East 
Asia and Europe, while genotypes II and III are less commonly detected (21). It has been 
demonstrated that genotypes II, III, and IV and subgroups Ib1 and Ib2 behave as five fully 
distinct serotypes. The implications of infection with the different genotypes are yet to be 
understood, but successive infections with different genotypes are possible as they don’t 
cross-neutralize (18).  
Besides from the variations on the VP1 region, variations on the NCCR lead to two different 
forms of BKPyV, referred to as archetype and rearranged variants. Archetype-NCCR is 
divided into five sequence blocks (Figure 2) named O, which contains the ORI, and P, Q, R 
and S, which contain regulatory regions for gene transcription (22). Rearrangements in the 
NCCR during viral replication usually involve duplications and deletions leading to the 
appearance of different rearranged-NCCR. These variants are more commonly found in the 
plasma and tissues of individuals with BKPyV-associated diseases (22,23). Archetypal 
variants of BKPyV are predominant in the urine, and are thought to be the transmissible 
forms of the virus, as they can be found in both healthy and diseased individuals (24). While 
the role of these variants in the development of BKPyV-associated diseases is not well 
established, it has already been shown that unlike rearranged strains, archetypal forms of 
BKPyV replicate poorly in cell culture (25). More recent studies have demonstrated that 
rearrangements on the NCCR lead to the decrease of viral miRNA production. This could 
result in an increase on the viral replication through the increase of TAg expression, since 
miRNAs are known to target TAg mRNAs to degradation (17). In this context, it has been 
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proposed that rearrangements in the NCCR might constitute an adaptation of the virus to 
enhance viral replication.  
 
1.1.3. BKPyV replication cycle 
The infection with BKPyV starts with the attachment of the virion to the host cell, followed by 
entry, genome expression and replication, assembly and release of the viral progeny (Figure 
3).   
 
Figure 3. Schematic representation of BKPyV replication cycle. BKPyV infection starts with the attachment of 
the virions to the host cell by binding to the ganglioside receptors (mainly GT1b and GD1b). Then, the virions are 
internalized through a caveolae-mediated endocytic pathway (1).  Inside the cell, the virus is transported along the 
microtubules towards the endoplasmic reticulum (ER; 2) where the uncoating process begins (3). The partially 
uncoated viruses subsequently gain access to the cytosol and the viral genome is transported into the nucleus 
through the nuclear pore complex due to VP2 and VP3 nuclear localization sequences (NLS) and the importin 
α/β1-mediated import pathway (4). Once the viral genome enters the nucleus, the early gene expression begins. 
Early proteins are then translocated to the nucleus promoting genome replication and late gene expression (5). 
After translation of viral mRNAs in the cytosol (6), VP1, VP2 and VP3 gain access to the nucleus where they self-
assemble around newly synthetized viral DNA (8). Progeny virions start to accumulate in the nucleus (9) and their 
release from infected cells is thought to occur mainly upon cell lysis. However, a non-lytic egress as also been 
described. (Adapted from Solis, et al., 2019) 
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Entry of the virus 
In order to start the infection, the viral particle must attach to the host cell through the binding 
of viral VP1 with specific cell receptors. These receptors have been identified as 
gangliosides, one type of glycosphingolipids, composed of a ceramide chain and an 
oligosaccharide to which one or more sialic acid residues are linked. α(2,8)-disialic acid motif 
on b-series gangliosides has shown to be required for this interaction, thus BKPyV can 
interact with the gangliosides GT1b, GD1b, GD2 and GD3 (26,27). Despite this, it has 
already been demonstrated that BKPyV genotype IV is capable of establishing an infection 
through a ganglioside-independent pathway, showing that different BKPyV genotypes might 
present different cellular tropisms (18). 
Following attachment to the cell surface, BKPyV is internalized through a caveolae-mediated 
endocytic pathway. Inside the cell, the virus is transported along the microtubules towards 
the endoplasmic reticulum (ER) where the uncoating process begins. In this process there 
seems to be the involvement of the ER protein disulfide isomerase which promotes 
conformational changes in VP1 molecules, providing the initial step for the capsid 
disassembly (28). Furthermore, proteins of the ER-associated degradation (ERAD) pathway, 
that are normally involved in the removal of misfolded proteins from the ER for proteasomal 
degradation, have been implicated as a mechanism used by the virus to escape from the ER 
to the cytosol (29).  
Once in the cytosol and after partial uncoating, nuclear localization sequences (NLS) of VP2 
and VP3 are exposed and thought to be used by the importin α/β1-mediated import pathway 
to transport the viral genome into the nucleus through the nuclear pore complex. However, 
an alternative route for genome entry into the nucleus has also been suggested to be 
present, as the BKPyV NLS mutation only attenuates the infection (30).  
 
Gene expression and genome replication  
When in the nucleus, the viral genome remains episomal in host cells (11). Soon after the 
genome enters the nucleus, cellular transcription factors bind to the early promotor leading to 
the expression of early proteins. After translation in the cytosol, TAg is transported into the 
nucleus where it binds to the ORI, leading to the recruitment of the cellular replication 
complex and to the unwinding of the double stranded DNA through its helicase activity, 
mediating the initiation of BKPyV genome replication. Additionally, TAg stimulates cell cycle 
progression and prevents apoptosis, by binding to the tumor suppressor proteins pRb, p107 
and p130, and p53, respectively (31). tAg has also been associated with cell cycle 
Evaluation of antiviral drugs against BK polyomavirus 
 
Carolina Conceição  17 
progression through inactivation of the protein phosphatase 2A (32). After the onset of DNA 
replication, in a process promoted by TAg, late genes are transcribed leading to the 
expression of the structural proteins and also agnoprotein (16). Agnoprotein is a small 
regulatory protein which seems to play important roles during the viral replication cycle, 
including regulation of gene expression, genome replication, and also virion assembly and 
release (33). 
 
Assembly and release of viral particles 
After translation in the cytosol, the structural proteins VP1, VP2 and VP3 are imported into 
the nucleus where the assembly of new viral particles takes place. At 2 days post-infection 
(dpi), progeny virus start to accumulate in the nucleus, forming nuclear inclusions that can be 
seen by electron microscopy in tubular epithelial cells from kidney biopsies or excreted in the 
urine as decoy cells, which are virally infected epithelial cells characterized by large nuclear 
viral inclusions (34,35). 
As for the release of the newly formed virus from infected cells, the knowledge is still very 
limited. Generally, it is suggested that the virus egress from the cell occurs by passive means 
such as host cell lysis, which has already been observed in RPTEC (human renal proximal 
tubular epithelial cells) (34). However BKPyV-infected cells rarely exhibit strong cytopathic 
effects (36). Furthermore, non-lytic egress for BKPyV progeny, although in smaller scale, has 
already been demonstrated (37). Even though further studies are needed in this subject, 
evidence points out that both lytical and non-lytical release of BKPyV progeny might occur. 
 
1.2. Primary infection, latency and reactivation 
BKPyV infection is ubiquitous, with a seroprevalence of over 80% among the adult 
population. Primary infection typically occurs during early childhood, with studies having 
shown that by the age of 10 approximately 70% of children present detectable serum 
antibodies against BKPyV (38). This primary infection is usually asymptomatic or associated 
with mild upper respiratory symptoms. The route of transmission is not yet fully established, 
but evidences of a primary upper respiratory infection, particularly in the tonsils, suggests 
that the virus is most likely transmitted through a respiratory route (39). However, other 
routes of transmission are also being proposed including fecal-oral, urino-oral, blood 
transfusion or organ transplantation (16,40). From the respiratory tract, presumably following 
a primary viremia, the virus is thought to disseminate to other sites of infection, including 
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mainly the urinary tract and the kidney. Following primary infection, BKPyV establishes a 
lifelong persistent infection mainly on epithelial cells of the urinary tract and the kidney, 
however, it is still unclear if the virus persists with a minimal replication, or if it enters a true 
viral latency. Occasional reactivations of the persistent virus occur that manifest as 
asymptomatic viruria with BKPyV loads of <5 log10 copies (c)/mL (41,42).  
In immunocompetent individuals, the virus remains clinically silent throughout the life of the 
host. However, under immunosuppressing conditions, typically immunosuppressive disease 
or treatment, viral reactivation might occur. The major clinical complications of BKPyV 
reactivation are PyVAN and hemorrhagic cystitis in kidney and hematopoietic stem cell 
transplant recipients, respectively (5). Less commonly BKPyV-associated clinical 
manifestations include interstitial pneumonitis, retinitis, native kidney nephritis and 
meningoencephalitis, described particularly in severely immunocompromised individuals 
such as patients with acquired immune deficiency syndrome (43). 
 
1.3. Polyomavirus-associated nephropathy 
PyVAN most commonly occurs in kidney transplant recipients due to BKPyV reactivation, 
with a prevalence rate that ranges from 1 to 10% in these patients (44). After reactivation, 
BKPyV replication in tubular epithelial cells results in cytopathic changes in those cells. The 
progress of the infection leads to tubular cell injury and interstitial inflammation that 
characterize PyVAN. Persistent PyVAN eventually leads to tubular atrophy, interstitial fibrosis 
and loss of function(45), which can potentially result in graft loss in 10 to 80% of the cases 
(46).  
Several factors have been described to modify the risk of BKPyV reactivation. However, 
immunosuppressive therapy is thought to be the one that has the major role in this 
reactivation. Rather than a specific therapy, it has been described that the overall degree of 
immunosuppression is responsible for increasing the risk. In fact, the development of more 
potent immunosuppressant drugs, such as tacrolimus and mycophenolate mofetil, have led 
to an increase on the PyVAN incidence rate in kidney transplant recipients (47).  
Other than immunosuppressive therapy, a variety of weekly associated risk factors have also 
been described to increase BKPyV reactivation. The preferential occurrence of PyVAN after 
kidney transplants over other solid organ transplants, even with comparable levels of 
immunosuppression (48), points out that the process of kidney transplantation itself and the 
resultant renal injury, might have a role on BKPyV reactivation. This includes prolonged cold 
ischemia time, delayed graft function and ureteral stent placement. Other transplant-related 
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risk factors that are usually referred to include degree of human leukocyte antigen (HLA) 
mismatch, donor BKPyV seropositivity, recipient BKPyV seronegativity, donor and recipient 
older age, recipient male gender and previous graft loss due to PyVAN. Prolonged pre-
transplant dialysis has also been pointed out as a potential risk factor for PyVAN 
development (5,16,49). 
Interestingly, the donor’s BKPyV strain reactivation has been suggested to be the one 
involved on PyVAN development. Consequently, genotype mismatch between the donor and 
the recipient neutralization profiles and their subsequently replicating strain before transplant 
might significantly increase the risk of BKPyV reactivation (50). 
 
1.3.1. Early screening and diagnosis 
Clinically BKPyV reactivation is asymptomatic, and in case of PyVAN development it only 
manifests as a deterioration in allograft function. The first evidence of BKPyV reactivation is a 
high-level BKPyV viruria with decoy cells shedding, followed by viremia (51). In kidney 
transplant recipients it is estimated that approximately 50% of the patients who present high-
level viruria evolve to viremia 2 to 6 weeks later, and that 50% of those who develop viremia 
are diagnosed with PyVAN 2 to 6 weeks later (52).  
Because no efficient and safe antiviral therapies against BKPyV are yet available, screening 
for BKPyV replication in urine and blood has become the key recommendation for kidney 
transplant recipients. This allows an early intervention, which to date consists mainly in 
modulating the immunosuppressive treatment, in order to prevent the development of PyVAN 
and ultimately graft loss (52).  
According to the Guidelines from the Infectious Diseases Community of Practice of the 
American Society of Transplantation, current recommendations point that kidney transplant 
recipients should be screened for BKPyV DNA loads in plasma by quantitative polymerase 
chain reaction (PCR)-based techniques, first monthly until month 9, then every 3 months until 
2 years post-transplant. This screening allows the identification of patients that should be 
considered for a preemptive treatment for PyVAN, however, prior to reducing 
immunosuppression and risking the precipitation of acute rejection, BKPyV viremia should be 
confirmed within 3 weeks. BKPyV DNA plasma loads sustained above 3 log10 c/mL, but 
below 4 log10 c/mL define probable PyVAN, and above 4 log10 c/mL define presumptive 
PyVAN. Screening for BKPyV reactivation can also be performed in the urine, although these 
methods are usually less preferred because of their low positive predictive values. In this 
case, either urine cytology for decoy cells or BKPyV DNA loads in urine by quantitative PCR-
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based techniques can be performed, 2 times a week for the first 3 months, then monthly until 
month 6, then every 3 months until 2 years post-transplant. If decoy cells are detected or if 
urine BKPyV DNA loads increase above 7 log10 c/mL, patients should be tested for BKPyV 
viremia (52).  
Although a BKPyV DNA plasma load above 4 log10 c/mL can diagnose a presumptive 
PyVAN, kidney biopsy remains the gold standard for definitive diagnosis of PyVAN. Because 
of the focal nature of the infection, it is recommended that a minimum of two biopsy cores are 
taken, preferentially containing medullary tissue, which is a significant reservoir for BKPyV 
infection, in order to avoid false negatives. The diagnosis of PyVAN is made upon 
identification of cytopathic changes in the tubular epithelial cells of the biopsy tissue. Since 
PyVAN and acute rejection might resemble morphologically, the diagnosis can be confirmed 
by immunohistochemistry or in situ hybridization (52). 
 
1.3.2. Therapeutic approaches 
Because BKPyV lacks a specific target, the search for a specific and safe antiviral against 
this virus becomes more difficult, and to date, none is still available. As such, the mainstay 
approach for persistent BKPyV replication and PyVAN in kidney transplant recipients is to 
reduce the immunosuppressive treatment. This strategy allows the reconstitution of the 
patients’ immune system, which becomes capable of controlling the infection. Although not 
all patients exhibit the same response, an efficient clearance of BKPyV viremia and the 
preservation of allograft function has been described in a high percentage of patients in 
several studies (52,53). Despite this, by reducing immunosuppression there is a risk of 
precipitating acute rejection. To prevent this from occurring, the immunosuppression 
reduction must be done in a stepwise manner with close monitoring of serum creatinine 
levels and BKPyV viremia, at least every two weeks until viremia clearance (52).  
The immunosuppressive regimen for kidney transplant recipients may vary between centers 
but usually consists of a calcineurin inhibitor, such as cyclosporine A and tacrolimus, an 
antimetabolite, such as azathioprine and mycophenolate mofetil, and a corticosteroid (54). 
Regarding the adjustment of the immunosuppressive treatment, there is no single approach 
and different strategies have been suggested. One of these approaches consists to first 
reduce the calcineurin inhibitor or the antiproliferative drug, followed by a dose reduction of 
the other drug and then discontinuation of the antiproliferative drug (52). Alternatively, other 
approaches include switching to less potent drugs, like for example, from tacrolimus to 
cyclosporine A (a less potent calcineurin inhibitor) (55), from the calcineurin inhibitor to 
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sirolimus, or from mycophenolate mofetil to sirolimus (56,57) or leflunomide (58–60). 
Successful outcomes have been reported with all these different strategies, however, that is 
still no randomized controlled trial that can recommend one over the others.  
In addition to the adjustments in the immunosuppressive treatment, and despite no specific 
antiviral against BKPyV is yet available, the off-label use of agents with potential anti-BKPyV 
activity in patients with PyVAN has been reported. These includes cidofovir, fluoroquinolones 
and intravenous immunoglobulins (IVIGs). However, as they are often used in combination 
with immunosuppression reduction and randomized controlled trials are still lacking, it is 
difficult to make strong conclusions about their efficacy (61). 
Novel therapeutic approaches against BKPyV are starting to appear. These include adoptive 
T cell therapy, that is starting to be studied to treat BKPyV-associated diseases (62,63). 
Furthermore, a vaccine for prevention of cytomegalovirus and BKPyV reactivation is currently 
under evaluation on a phase I clinical trial (64).  
 
Leflunomide 
Leflunomide presents both immunosuppressive and antiviral properties, being currently 
approved for the treatment of rheumatoid arthritis. Its antiviral effects are attributed to its 
active metabolite A771726 which inhibits protein kinase activity and the synthesis of 
pyrimidines. In vitro, leflunomide has already shown to interfere with BKPyV replication in 
RPTEC (65). Several studies have reported the use of leflunomide, often combined with 
reduction of the immunosuppressive treatment, and clearance or reduction of BKPyV viremia 
has been described (58–60). However, determining its efficacy remains difficult since 
therapeutic outcomes change between studies (53) and no randomized controlled trials have 
been performed. Additionally, significant toxic effects have been described when using this 
drug including hepatitis, hemolysis, thrombotic microangiopathy, bone marrow suppression, 
and fungal pneumonia (52).  
 
Mammalian target of rapamycin inhibitors 
Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, are 
immunosuppressive agents that also exhibit antitumoral activity by inhibiting cell-cycle 
progression and proliferation. In vitro, they have shown to decrease BKPyV replication by 
interfering with mTOR–SP6‐kinase activation (66). Different studies have reported that 
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kidney transplant recipients receiving mTOR inhibitors compared to those receiving standard 
immunosuppressive regimens exhibit a more efficient clearance of BKPyV viruria and viremia 
or even lower risks of developing BKPyV viremia (56,57,67). Although its use seems 
promising in preventing PyVAN, further studies are needed, particularly regarding their 




Cidofovir is a nucleoside analog and viral DNA polymerase inhibitor only approved for the 
treatment of cytomegalovirus retinitis. The antiviral effect against BKPyV has already been 
demonstrated in vitro in RPTEC, however, the mechanism behind this effect remains unclear 
(70). Treating kidney transplant recipients with cidofovir alongside with reducing 
immunosuppression has shown favorable outcomes in some studies (71,72), whereas others 
claim no advantage with this treatment (53). Despite this potential benefit in PyVAN, major 
adverse effects associated with the use of this drug include nephrotoxicity and uveitis, with 
the first one limiting its use in kidney transplant recipients (52,73). 
Brincidofovir is an experimental pro-drug of cidofovir, orally administrated and substantially 
less nephrotoxic. In vitro, it has shown to decrease BKPyV replication in RPTEC more 
efficiently when compared to cidofovir, and also to exhibit fewer toxicity (74). Successful 
outcomes have been obtained with this drug in two different studies (75,76), however, 




Fluoroquinolones are a family of broad-spectrum antibiotics that have shown to present an 
antiviral effect against BKPyV in vitro, possibly by inhibiting the helicase activity of TAg (77). 
Initial studies have reported a prophylactic effect with the use of fluoroquinolones in both 
kidney and hematopoietic stem cell transplant recipients (78,79). However, a double-blind, 
placebo-controlled randomized trial failed to demonstrate the efficacy of a 3-month course of 
levofloxacin on lowering BKPyV viruria, as well as it shown an increased risk of bacterial 
resistance (80). These results do not support the use of fluoroquinolones on the prevention 
of BKPyV reactivation. 
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Intravenous immunoglobulins 
Because of the high seroprevalence of BKPyV in the population, commercially available IVIG 
preparations have been demonstrated to contain high titers of potent BKPyV neutralizing 
antibodies (NAb). Its antiviral effect is attributed to direct neutralizing activity but also to 
indirect immunomodulatory effects (81). Some studies have described the use of IVIG in 
combination with reduced immunosuppression with beneficial outcomes (82,83). Additionally, 
a study suggesting that higher NAb titers against the replicating strain of BKPyV were 
associated with a lower risk of BKPyV reactivation, supports the potential benefit of 
administering NAb either as a preventive or a therapeutic strategy (50). However, no 
controlled studies have yet been reported. 
 
Cellular immunotherapy 
Immunosuppression is thought to be the main cause of BKPyV reactivation. In this context, 
the adoptive transfer of BKPyV-reactive T cells may help to restore the immune response of 
these patients, thus allowing it to control viral replication and reducing the complications 
associated with this reactivation. This approach has already shown to be effective to treat 
other virus-associated diseases, particularly associated with Epstein-Barr virus and 
cytomegalovirus (84,85), in immunocompromised patients. More recently, the use of this 
immunotherapy started to be studied to treat diseases caused by BKPyV infection. The 
immunodominant epitopes of BKPyV to be used on T cell expansion are not yet defined, 
nevertheless, it is already reported the in vitro expansion of BKPyV-reactive T cells using 
overlapping peptide mixes of the five BKPyV proteins (VP1, VP2, VP4, TAg and tAg) (62). 
One study described the use of adoptive T cell therapy with full resolution of the symptoms 
and viremia on a patient that who, following hematopoietic stem cell transplantation, 
developed hemorrhagic cystitis due to BKPyV reactivation (63). Another promising study in 
this area described the use of adoptive transfer of virus-reactive T cells targeting BKPyV and 
four other viruses (Epstein-Barr virus, adenovirus, cytomegalovirus, and Human Herpesvirus 
6) known to cause frequent infections in immunocompromised patients, with a great clinical 
response (86). With further research in this area, adoptive T cell therapy can become a 
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1.4. Model systems for the study of BKPyV infection  
To better understand the virus’ structure, the replication cycle, the pathogenicity, and also to 
identify compounds with antiviral activity, both in vitro and in vivo models are crucial. Much of 
the knowledge regarding BKPyV in the past has been inferred from the much more studied 
polyomavirus SV40 (11,13). However, in the last years, a big effort to study BKPyV has been 
made as it is increasingly recognized as responsible for an important infection affecting 
mostly kidney and hematopoietic stem cell transplant recipients using the new potent 
immunosuppressive protocols.  
To date, BKPyV has been known to replicate only in human and monkey cells. Vero cells 
were the first cells used to isolate BKPyV and currently, this African green monkey kidney 
cell line is still widely used in research to replicate the virus (3). RPTEC, however, constitute 
a more appropriate model for the study of BKPyV, as they are one of the major target cells of 
the virus in vivo (34). The problem regarding these cells is that primary RPTEC divide slowly 
and quickly enter into replicative senescence. Because of that, human telomerase reverse 
transcriptase (hTERT) immortalized RPTEC (RPTEC/TERT1), which have shown to maintain 
their functional characteristics, also started to being used (87). Other kidney cell lines of both 
human and monkey origin, human embryonic kidney 293 (HEK293) cells and CV-1 cells, 
respectively, are also used (88,89). Interestingly, other cell types allow the replication of 
BKPyV, including human salivary gland cells (90) and human embryonic lung fibroblast cells, 
such as MRC-5 (91). The cells mentioned above successfully allow the propagation of 
rearranged forms of BKPyV. Archetype forms, however, due to low TAg expression replicate 
poorly in cell culture. The human endothelial cell line HUV-EC-C was the first one to allow 
the propagation of archetypal BKPyV (25). More recently, archetype forms of BKPyV have 
also shown to be able to replicate in cell lines transformed with the SV40 TAg including 
293TT and COS-7 cells, cell lines derived from HEK293 and CV-1 cells, respectively (24).  
Regarding the virus, recombinant viruses with both rearranged and archetype NCCR are 
commonly used. Rearranged strains include Gardner, Dunlop and TU strains, and as for the 
archetypal strains, WW and WWT strains are among the most common (92).  
Alternatively, virus-like particles (VLPs) can be used. VLPs consist on capsid-like particles 
that spontaneously self-assemble upon overexpression of the major capsid protein VP1, but 
that devoid of the virus’ genetic material. These models can be produced in a variety of 
different systems including Escherichia coli, yeast, insect cells and mammalian cells (93). 
Additionally, these systems can be co-transfected with vectors encoding a reporter gene, 
enabling the quantification of the particles that enter target cells. Although these models 
cannot be used to study BKPyV replication, as they do not contain the viral genome, they 
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have provided useful information on the viral structure and on the early steps of the viral 
cycle, including interactions with cell surface receptors and entry (13,94). Finally, VLPs seem 
to have a promising application in the development of vaccines that could be used prior to 
transplantation (93).  
Although in vitro models are sufficient to provide information on the virus replication cycle, 
animal models are needed in order to better understand the mechanisms underlying the 
virus-associated diseases but also for conducting preclinical tests on potential new antiviral 
drugs and vaccines. Because of the narrow host range of BKPyV the development of small 
animal models to study BKPyV infection was hampered. In fact, BKPyV DNA replication is 
inhibited by a restriction factor found in murine cells (95). Previous attempts to develop an 
animal model for BKPyV infection have already been carried out (91). However, an animal 
model that closely mimics BKPyV infection in humans is still lacking.  
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2. Aims of this study 
Over the last years, the development of more potent immunosuppressive agents has made 
BKPyV emerge as an important pathogen responsible for serious complications such as 
PyVAN in kidney transplant recipients. The lack of specific and safe antiviral agents that can 
efficiently stop BKPyV replication still poses significant challenges, as PyVAN can lead to 
alterations in the kidney’s structure, loss of function and potentially graft loss.  
In this context, this project focused on studying the efficacy of two drugs - NA-17 and TN-18 - 
against BKPyV. For that purpose, this study was divided in different tasks in order to provide 
a characterization of the drugs’ effect against BKPyV. 
First, the effect of both drugs was assessed on Vero cells, a monkey kidney cell line, to 
determine whether they had potential to proceed for further testing. Then, the drugs that 
exhibited an antiviral effect on the first step, were submitted to a more detailed study on a 
better in vitro model of the virus target in vivo, RPTEC/TERT1. On this second stage a 
selected range of concentrations of each drug was used to characterize their effect against 
the virus. The inhibition of BKPyV infection for each concentration of both drugs was 
determined and used to calculate the respective effective concentrations 50% (EC50). Then, 
as both drugs were known to exhibit an antimetabolite effect, the alterations on the 
extracellular BKPyV DNA load were measured for each concentration tested, and a 
correspondence was tried with the variations on the release of infectious progeny.  
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3. Materials and Methods 
3.1. Cell culture 
Vero cells (ATCC, CCL-81) were maintained in Dulbecco's modified Eagle medium (DMEM; 
Gibco, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS). 
RPTEC/TERT1 (Evercyte, CHT-003-0002) were maintained in renal epithelial growth 
medium (REGM) supplemented with 0.1% recombinant human epidermal growth factor, 
0.1% hydrocortisone, 0.1% epinephrine, 0.1% insulin, 0.1% triiodothyronine, 0.1% 
transferrin, 0.1% GA-100 (gentamicin and amphotericin B) and 0.5% FBS (REGM Bulletkit; 
Lonza). All cells were kept in a humidified incubator at 37°C with 5% CO2 and propagated as 
described by the manufacturer.  
 
3.2. Virus 
3.2.1. Virus stock production 
BKPyV stock was produced by transfecting Vero cells with BKPyV Dunlop genome. Briefly, 
the pUC19pBKv(34-2) plasmid, provided by Professor Walter Atwood (Brown University, 
USA), was amplified after transformation of chemically competent Escherichia coli 
(Invitrogen, C404010). The plasmids produced were digested with BamHI to separate 
BKPyV genome from the vector plasmid and were used to transfect Vero cells. Cells were 
kept in culture until cytopathic effects were observed. After that time, cell culture 
supernatants were harvested and submitted to 3 freeze/thaw cycles that allowed cell lysis 
and release of the virions. BKPyV was further amplified by successive infection of Vero cells, 
and the cell culture supernatant of infected cells was kept. The viral stock produced was 
stored at -80°C.  
 
3.2.1. Virus stock titration 
BKPyV stock was titrated in Vero cells and RPTEC/TERT1. For the titration, cells were 
plated and infected 24 h later with the viruses in 10-fold serial dilutions ranging from 10-1 to 
10-8. After 2 h of incubation for viral adsorption, the supernatants were removed and replaced 
with the adequate cell growth medium. At 72 h post-infection (hpi), cells were washed, fixed 
and immunostained as described below. The stocks’ titer was expressed in 50% tissue 
culture infectious dose (TCID50)/mL and determined using Reed and Muench calculator (96) 
(Brett D. Lindenbach, 2008).  
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3.3. Infection and drug treatment 
Cells were plated in 96-well plates for confluence at day 5 and infected 24 h later with BKPyV 
Dunlop at a multiplicity of infection (MOI) of 1 in DMEM. After 2 h of incubation in a 
humidified incubator at 37°C with 5% CO2, the supernatants were removed and replaced with 
the adequate cell growth medium (for Vero cells, medium supplementation with FBS was of 
5%) with or without the drugs for 3 days. Controls containing only cells or only cells with the 
drugs were also included. All experiments were performed in triplicates. 
Prior to each experiment, NA-17 and TN-18 drugs were freshly dissolved in dimethyl 
sulfoxide (DMSO) and H2O, respectively. NA-17 was further diluted in cell growth medium 
with DMSO at 1:1000 in 10-fold serial dilutions ranging from 10 nM to 100 µM. TN-18 was 
further diluted in cell growth medium in 10-fold serial dilutions ranging from 10 nM to 1 mM. 
DMSO controls matching the DMSO concentration in 100 µM NA-17 (1:1000) were included 
in all experiments. The drugs’ structures are protected under laboratory confidentiality and 
therefore, they are only represented by a code. 
 
3.4. Immunofluorescence staining, microscopy, and digital image 
processing 
Cells were washed with phosphate-buffered saline (PBS) at 72 hpi, fixed with 3.7% 
paraformaldehyde (PFA) in PBS for 10 min and permeabilized with 0.5% Triton X-100 in 
filtered CSK (cytoskeletal buffer; 10 mM PIPES pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 
mM MgCl2, 1 mM EDTA) and H2O (1:1) for 15 min, both at room temperature. Fixed cells 
were then incubated with the primary antibody for 1 h at room temperature, and the 
secondary antibody for 30 min at room temperature in the dark. The primary antibody used 
was mouse monoclonal anti-SV40 TAg (Pab416; 1:500; Abcam), and the secondary antibody 
used was goat anti-mouse IgG conjugated with Alexa Fluor Plus 488 (1:1000; Thermo Fisher 
Scientific), both diluted in PBS/Tween 0.1%. Cell nuclei were stained with DAPI (1:1000; 
Santa Cruz Biotechnology). 
Images were collected using an inverted microscope (Axio Vert.A1 and Colibri 7 light source, 
Zeiss). For cell counting, pictures from two random fields per well were taken and DAPI and 
TAg stained nuclei were automatically counted using QuantIF (Figure 4), an ImageJ 
(National Institute of Health, Bethesda, MD, USA) macro (97).  
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Figure 4. Description of the QuantIF macro. Two pictures of each field must be taken, one corresponding to the 
specific staining (infected cells) and the other corresponding to the DAPI staining (total cells), for analysis by the 
QuantIF macro. Both the DAPI staining image (A) and the specific staining image (B) are then converted to a 
staining mask, (C) and (D), respectively. A third mask corresponding to the nuclei of the immunostained cells is 
created (E). Finally, DAPI stained and immunostained cells’ nuclei are counted using the DAPI and the 
immunostained cells’ nuclei staining masks. (Adapted from Handala, et al., 2019) 
 
3.5. Extracellular BKPyV DNA load 
To quantify the extracellular BKPyV DNA loads, cell culture supernatants of infected cells 
both untreated and treated with the drugs were harvested at 72 hpi and stored at 4°C until 
quantification by quantitative real-time PCR (qPCR) using primers and a probe targeting a 
common region of the VP1 and VP2 genes in the BKPyV genome. Reactions were 
performed in a total volume of 25 μL containing 2X TaqMan Universal PCR Master Mix 
(Applied Biosystems), 10 µM of each primer and the 6-carboxyfluorescein (FAM)-labeled 
probe, and 5 μL of supernatant. Amplification was performed using an ABI Prism 7900HT 
Sequence Detection System (Applied Biosystems) with the following PCR program: initial 
step of 2 min at 50°C followed by 1 cycle at 95°C for 10 min, and 45 two-step cycles at 95°C 
for 15 s and 60°C for 1 min. BKPyV DNA loads were determined using a standard curve 
generated by amplification of four quantification standards containing different known 
concentrations of BKPyV DNA (9 000 000 to 9000 c/mL of the pUC19pBKv(34-2) plasmid in 
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10-fold serial dilutions). For every experimental condition triplicates were analyzed. A 
BKPyV-negative control was added to each run. 
 
3.6. Release of infectious progeny 
To detect the release of infectious progeny into the supernatant, cell culture supernatants of 
infected cells both treated and untreated with each drug were harvested at 72 hpi and stored 
at 4°C. Supernatants were used to infect new cells for 2 h and were then removed and 
replaced with fresh cell growth medium. At 72 hpi, cells were washed, fixed and 
immunostained as described above.  
 
3.7. Calculation of the effective concentrations 50%  
GraphPad Prism 8 software (GraphPad, La Jolla, CA) was used for curve fitting to determine 
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4. Results 
4.1. Effect of NA-17 and TN-18 on BKPyV infection on Vero cells 
4.1.1. Inhibition of BKPyV infection 
First, the effect of both drugs, NA-17 and TN-18, on inhibiting BKPyV infection was evaluated 
on Vero cells. For such, Vero cells were infected with BKPyV and different concentrations of 
each drug were added 2 hpi. Cells were fixed at 72 hpi and immunostained for TAg. Cell 
nuclei were stained with DAPI. Then, pictures were taken for cell counting, and DAPI and 
TAg stained nuclei were automatically counted using QuantIF, an ImageJ macro. Results 
show an inhibition of BKPyV infection only with the highest concentration tested for each 
drug (Figure 5A and B). Of note, NA-17 at concentrations from 10 μM and TN-18 at a 
concentration of 1000 μM reduced the total cell number per field (Figure 5C and D). 
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Figure 5. Effect of increasing concentrations of NA-17 and TN-18 on the inhibition of BKPyV infection on 
Vero cells. (A, B) Vero cells infected with BKPyV were treated 2 hpi with the indicated concentrations of NA-17 
(A) and TN-18 (B). Cells were fixed at 72 hpi and immunostained for TAg. Cell nuclei were stained with DAPI. 
Pictures were taken for cell counting, and DAPI and TAg stained nuclei were automatically counted using 
QuantIF, an ImageJ macro. The percentage of inhibition of BKPyV infection for each concentration of the drugs 
was calculated in relation to a control of infected Vero cells without any treatment. Determinations were performed 
in triplicate, each corresponding to the analysis of two pictures. The mean values are shown, and the error bars 
represent the standard deviations of means between triplicates. Curve fitting was obtained using GraphPad Prism 
8 software. (C, D) Total cell number of infected Vero cells both untreated and treated with different concentrations 
of NA-17 (C) and TN-18 (D). The number of cells in each picture was counted using QuantIF. The mean values 
are shown, and the error bars represent the standard deviations of means between triplicates.  
 
Since an inhibition of BKPyV infection on Vero cells was observed for NA-17 and TN-18, the 
effect of both drugs was then investigated in RPTEC/TERT1, an immortalized cell line of the 
major target cells of BKPyV in vivo. 
 
4.2. Effect of NA-17 and TN-18 on BKPyV infection on RPTEC/TERT1 
4.2.1. Inhibition of BKPyV infection 
To investigate the effect of both drugs on inhibiting BKPyV infection on RPTEC/TERT1, we 
proceeded like previously for Vero cells. Similarly to what we observed for Vero cells, the 
lowest concentrations tested for both drugs provided none to a very discrete effect. For NA-
17 an inhibitory effect on BKPyV infection starts to be observed with a concentration of 10 
μM and seems to increase in a concentration dependent manner, as it increases with a 
concentration of 100 μM. For TN-18, like previously observed on Vero cells, an antiviral 
effect is only evident for the highest concentration tested (Figure 6A and B). Of note, unlike 
observed on Vero cells, none of the concentrations tested for both drugs seems to have a 
significant impact on the total cell count (Figure 6C and D). 
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Figure 6. Effect of increasing concentrations of NA-17 and TN-18 on the inhibition of BKPyV infection on 
RPTEC/TERT1. (A, B) RPTEC/TERT1 infected with BKPyV were treated 2 hpi with the indicated concentrations 
of NA-17 (A) and TN-18 (B). Cells were fixed at 72 hpi and immunostained for TAg. Cell nuclei were stained with 
DAPI. Pictures were taken for cell counting, and DAPI and TAg stained nuclei were automatically counted using 
QuantIF, an ImageJ macro. The percentage of inhibition of BKPyV infection for each concentration of the drugs 
was calculated in relation to a control of infected RPTEC/TERT1 without any treatment. Determinations were 
performed in triplicate, each corresponding to the analysis of two pictures. The mean values are shown, and the 
error bars represent the standard deviations of means between triplicates. Curve fitting was obtained using 
GraphPad Prism 8 software. (C, D) Total cell number for infected RPTEC/TERT1 both untreated and treated with 
different concentrations of NA-17 (C) and TN-18 (D). The number of cells in each picture was counted using 
QuantIF. The mean values are shown, and the error bars represent the standard deviations of means between 
triplicates. 
 
In order to determine the EC50 for both drugs, curve fitting based on the data obtained with 
the RPTEC/TERT1 was performed using GraphPad Prism 8 software (Figure 6). An EC50 of 
190 μM and an EC50 of 682 μM were calculated for NA-17 and TN-18, respectively (Table 1).  
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Table 1. Calculated EC50 values for NA-17 and TN-18 tested on RPTEC/TERT1a 
Drug EC50 (μM) (95% CI) 
NA-17 190 (97.9 - 566) 
TN-18 682 (311 - 23 310) 
a EC50 values and the correspondent 95% confidence intervals (CI) were calculated based on the curve fitting 
performed using GraphPad Prism 8 software 
 
4.2.2. Effect on BKPyV genome replication 
Although the mechanism by which these drugs may present an anti-BKPyV effect is not 
established, they are known to exhibit an antimetabolite effect. In this context, next, we 
investigated their effect on the virus genome replication by measuring the extracellular 
BKPyV DNA load. Cell culture supernatants of infected RPTEC/TERT1 both untreated and 
treated with NA-17 and TN-18 were harvested at 72 hpi and BKPyV DNA load was 
measured by qPCR. Supporting the results obtained with immunofluorescence, the lowest 
concentrations tested for both drugs don’t seem to have any effect on inhibiting BKPyV 
replication (Figure 7). For NA-17 a decrease on BKPyV DNA load can be observed with the 
two highest concentrations. For TN-18 only the highest concentration seems to cause a 
decrease on BKPyV DNA load. Although an effect on viral DNA replication can be observed 
using the highest concentrations tested of these drugs, the decrease of extracellular BKPyV 
DNA load is very discrete, being for both cases <1 log10 c/mL, reaching a maximum inhibition 
of approximately 5% and 7% for NA-17 and TN-18, respectively. 
 
Figure 7. Effect of increasing concentrations of NA-17 and TN-18 on BKPyV DNA load.   RPTEC/TERT1 
infected with BKPyV were treated 2 hpi with the indicated concentrations of NA-17 (A) and TN-18 (B). 
Evaluation of antiviral drugs against BK polyomavirus 
 
Carolina Conceição  35 
Supernatants were harvested at 72 hpi and BKPyV DNA load was measured by qPCR. Determinations were 
performed in triplicate. The mean values are shown, and the error bars represent the standard deviations.  
 
4.2.3. Effect on the release of infectious progeny 
To determine whether the decrease in extracellular BKPyV DNA load corresponded to the 
release of infectious progeny, supernatants harvested at 72 hpi from BKPyV-infected 
RPTEC/TERT1 untreated and treated with different concentrations of each drug were used 
to infect freshly seeded RPTEC/TERT1. Immunofluorescence staining was performed at 72 
hpi like previously described and pictures were taken for cell counting. Results show an 
inhibition of infectious progeny release corresponding to the results found on extracellular 
BKPyV DNA load (Figure 8). This means that for NA-17 the release of infectious progeny 
decreased with the two highest concentrations tested, and for TN-18 only with the highest 
concentration. Of note, with the lowest concentrations tested of NA-17 and TN-18 an 
inhibition of approximately 20% and 40% in relation to the controls is already found, which 
does not correspond to the results obtained for the BKPyV DNA load, where differences from 
the controls were only observed with the highest concentrations. However, caution must be 
taken when analyzing these results since the infection of RPTEC/TERT1 using supernatants 









Figure 8. Effect of increasing concentrations of NA-17 and TN-18 on the release of infectious progeny.   
Supernatants harvested at 72 hpi from BKPyV-infected RPTEC/TERT1 untreated and treated with different 
concentrations of NA-17 (A) and TN-18 (B) were used to infect freshly seeded RPTEC/TERT1. 
Immunofluorescence staining for TAg was performed at 72 hpi. Cell nuclei were stained with DAPI. Pictures were 
taken for cell counting, and DAPI and TAg stained nuclei were automatically counted using QuantIF, an ImageJ 
macro. The percentage of inhibition of infectious progeny release for each concentration of the drugs was 
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calculated in relation to a control of fresh RPETC/TERT1 infected with the supernatants from untreated BKPyV-
infected RPTEC/TERT1. Determinations were performed in triplicate, each corresponding to the analysis of two 
pictures. The mean values are shown, and the error bars represent the standard deviations of means between 
triplicates. Curve fitting was obtained using GraphPad Prism 8 software. 
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5. Discussion 
A specific and safe antiviral that can efficiently stop BKPyV infection and prevent PyVAN 
progression is still in need. In this project, the effect of two drugs - NA-17 and TN-18 - 
against BKPyV replication was characterized in RPTEC/TERT1. We found out that the 
treatment with each drug 2 hpi resulted in a moderate inhibition of BKPyV infection, having 
been estimated EC50 values of 190 μM and 682 μM for NA-17 and TN-18, respectively.  A 
more detailed study of the effect of these drugs against BKPyV showed that with the highest 
concentrations tested, both NA-17 and TN-18 were responsible for a decrease on the 
extracellular BKPyV DNA load, that although discrete, corresponded also with an inhibition 
on the release of infectious progeny. 
Before proceeding to the study of the drugs on BKPyV-infected RPTEC/TERT1, a first assay 
was performed on Vero cells in order to determine if the drugs exhibited a potential antiviral 
effect against the virus. Vero cells were the first cells used to isolate BKPyV, and besides 
having shown to be permissive and to well replicate this virus, this cell line is easily 
cultivated, achieves confluence readily and does not require the use of specialized media 
(3,98). Because of this, this cell line is still widely used on basic research and constitutes an 
appropriate model for a first approach on evaluating the effect of a potential anti-BKPyV 
drug. First results obtained using Vero cells showed that 72 hpi an inhibition of BKPyV 
infection was obtained with 100 μM of NA-17 and with 1000 μM of TN-18. Although only the 
highest concentrations tested for each drug allowed an inhibition of the infection, a peak of 
BKPyV infection on Vero cells is expected between the 7 and 10 dpi (98), meaning that 
assays carried only until 3 dpi may not entirely reflect the effect of the drugs tested against 
the virus. As such, the anti-BKPyV effect observed in these preliminary results was 
considered sufficient to proceed with both drugs for further testing.  
On a second stage, we wanted to characterize the anti-BKPyV effect of both drugs on a 
better in vitro model. As mentioned before, the ideal cells for this study would be RPTEC, 
one of the major targets of the virus in vivo, however, working with primary cells comes with 
its challenges as they are harder to cultivate and exhibit a limited lifespan. To overcome 
these problems, we decided to use RPTEC/TERT1, an immortalized cell line of RPTEC. To 
start the characterization of the drugs’ effect on RPTEC/TERT1, the same assay previously 
performed on Vero cells was repeated on this cell line. Results obtained using 
RPTEC/TERT1 showed a better anti-BKPyV effect of both drugs on these cells. For NA-17 
an inhibition of the infection was observed from a concentration of 10 μM, that increased with 
the increase of the concentration. For TN-18, similarly to what we had observed on Vero 
cells, only the concentration of 1000 μM seemed to have an impact on inhibiting the infection, 
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but a higher inhibition was obtained using this second cell type. Curve fitting to these results 
allowed to estimate the EC50 values for NA-17 and TN-18 of 190 μM and 682 μM, 
respectively. These EC50 values are relatively high, showing only a moderate antiviral effect, 
however, the CI shown for these values reflect the high variability of these results, making 
them hard to interpret. The range of concentrations tested for each drug did not allow to 
calculate the EC90. Increasing these concentration ranges would provide more information on 
the drugs’ efficacy.  
As referred to before, although the mechanism by which these drugs may inhibit BKPyV 
infection is not established, both drugs are known to exhibit an antimetabolite effect. As such, 
it was expected that they interfered with viral genome replication. The inhibition of infection 
previously described for both drugs was determined with an immunofluorescence assay 
targeting TAg, which allowed to calculate the percentage of infection in each condition. 
However, TAg is a protein encoded by the early coding region of BKPyV genome, that is 
expressed prior to genome replication. For that reason, next, we decided to evaluate the 
effect of both drugs on viral genome replication by quantifying the extracellular BKPyV DNA 
load.  We chose to use extracellular BKPyV DNA only, because BKPyV was already proven 
to be efficiently released from RPTEC, so a similar behavior was expected with 
RPETC/TERT1 (99). Moreover, extracellular DNA load had already been used in previous 
studies to evaluate the effect of antiviral drugs on BKPyV-infected RPTEC (74). These 
results supported the previous ones, as they showed a decrease in BKPyV DNA load for the 
two highest concentrations of NA-17 and for the highest concentration of TN-18. However, 
the decreases observed are very discrete, being for both cases <1 log10 c/mL when 
comparing to the control. To better understand these results it would have been interesting to 
quantify the input of BKPyV DNA load (100). This would tell us how much of the DNA 
measured was effectively released from infected cells as a result of viral replication.   
In agreement with the decreases observed on BKPyV DNA load as a result of the treatment, 
an inhibition of infectious progeny release was found for the same concentrations. The main 
problem regarding these results is that low infection rates were obtained when using 
supernatants harvested 72 hpi to infect freshly seeded cells. The low number of infected cells 
increases the variability of the results obtained, making them hard to interpret. Furthermore, 
low infection rates were also obtained with the controls, most probably meaning that at 72 hpi 
the first replication cycle of the virus is not complete, and an efficient release of the progeny 
is not yet achieved. As described previously, the kinetics of BKPyV growth in RPTEC shows 
an increase on the extracellular DNA load at 3 dpi, reaching its peak at around 4 dpi (34,70). 
Because of this, a time point of 72 hpi has been largely used in studies regarding the 
evaluation of the antiviral effect of different drugs against BKPyV (70,74,77,100), which was 
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also chosen for our study. The results obtained, however, suggest a different kinetics of 
BKPyV infection on RPTEC/TERT1. As such, a study of the replication cycle of BKPyV on 
this cell line would help to better design the antiviral assay.   
In what concerns the cytotoxic effects of NA-17 and TN-18 a detailed study was not 
conducted. However, to provide a first impression on the potential toxicity of these drugs, the 
cell count obtained under each condition was included in the results. The cell counts on 
RPTEC/TERT1 showed that with the range of concentrations tested for each drug, a 
significant effect on cell number was not observed. Nevertheless, in order to take strong 
conclusions on their toxicity, more specific assays must be conducted. As the exact 
mechanism by which the drugs interfere with the infection is not known, different cytotoxicity 
assays should be performed. Taking in consideration the known antimetabolite effect of both 
drugs and knowing that BKPyV genome replication is dependent on cellular DNA 
polymerases, these should include the effect of both drugs on cellular DNA replication, for 
example by measuring bromodeoxyuridine incorporation. This will allow to calculate the 
cytotoxic concentrations 50% and 90% (CC50 and CC90), that together with the EC50 and the 
EC90, can be used to calculate the corresponding selectivity indexes (SI, calculated by 
dividing the respective CC by the EC). The SI is a much better parameter to evaluate the 
drugs’ efficacy in vitro, providing information on the selectivity of their antiviral effect. 
In addition to all the assays performed, to complete the characterization of the antiviral effect 
of these drugs it would be interesting to evaluate early and late gene expression. It would be 
particularly interesting to evaluate the impact on late proteins, such as VP1 or agnoprotein, 
as they are expressed only after viral genome replication takes place. This could be achieved 
for example by measuring mRNA levels by reverse transcription qPCR (RT-qPCR) or by 
performing Western blot, preferentially in different time points to provide an insight on the 
drugs’ temporal effect. 
Regarding the cell type used, we chose to use RPTEC/TERT1. Using this cell line gave us 
an advantage as it maintains the characteristics of primary RPTEC, the major target cells of 
the virus in vivo, while overcoming the limited lifespan of primary cells in culture. However, 
the lentivirus vector used to express the hTERT in this cell line contains SV40 genome 
sequences, including the ORI. These SV40 sequences could interfere with our assays due to 
their ability to replicate in the presence of BKPyV (101). In this context, the results obtained 
with this cell line might not entirely reflect the effect of our drugs on BKPyV-infected RPTEC. 
Overall our results show a moderate effect of both drugs tested against BKPyV infection. 
Results from the mathematical modeling of BKPyV replication in kidney transplant recipients 
show that an inhibition of over 80% of BKPyV replication must be achieved in order to obtain 
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a clearance of plasma and urine viral loads (102). The range of concentrations used for each 
drug allowed a maximum inhibition of infection of around 50%. Increasing these 
concentrations may allow to reach a higher inhibition of BKPyV infection. However, with 
higher concentrations more cytotoxic effects might appear, and the administration of such 
high concentrations in vivo may not be feasible. All together these results make us believe 
that the use of these drugs to stop BKPyV infection is limited, as other drugs have already 
shown a higher efficacy against BKPyV in vitro (74,77,100,103). 
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6. Conclusions and Future Outlooks 
BKPyV is considered ubiquitous among the population, and despite it establishes a lifelong 
persistent infection in the host, in immunocompetent individuals, it remains clinically silent 
throughout their lives. Under immunosuppressing conditions, however, viral reactivation 
might occur, being PyVAN one of the major clinical complications of BKPyV reactivation in 
kidney transplant recipients. In order to prevent the progression of the infection and the 
eventual graft loss, and since an efficient and safe antiviral against BKPyV is still lacking, the 
mainstay approach is to decrease the immunosuppressive treatment, allowing the patient’s 
immune system to fight the infection.  Nevertheless, this approach still comes with its risks as 
it does not guarantee an efficient clearance of BKPyV infection and can also precipitate an 
acute graft rejection. In addition to these adjustments in the immunosuppressive treatment, 
the off-label use of some agents with potential anti-BKPyV activity has been reported. And 
although some promising outcomes have already been described, the lack of randomized 
controlled trials makes it difficult to take strong conclusions about their efficacy. In this 
context the development and search for antiviral drugs that can efficiently stop BKPyV 
replication and improve clinical outcomes in PyVAN after kidney transplantation, has become 
of great interest. 
Taken together, the results from this study showed a moderate effect for both NA-17 and TN-
18 against BKPyV, with NA-17 exhibiting a relatively stronger effect. The treatment of 
BKPyV-infected RPETC/TERT1 with these drugs allowed, with the highest concentrations 
tested, an inhibition of BKPyV infection, and a decrease on viral DNA load and infectious 
progeny release.  
To evaluate these drugs’ activity against BKPyV we decided to evaluate their effect on viral 
DNA load, as an antimetabolite effect was expected with both drugs. However, to obtain a 
more detailed characterization of their antiviral activity and to better understand the 
mechanism by which they interfere with BKPyV replication, their effect on early and late gene 
expression could also be evaluated.  
As referred to before, other drugs have already been tested in vitro against BKPyV with 
promising results. In this study, the EC50 values estimated were of 190 μM and 682 μM for 
NA-17 and TN-18, respectively, which are considerably high, making us believe that these 
drugs would have a limited effect in vivo. Nevertheless, it would be important to calculate the 
SI in order to understand the selectivity of the drugs’ antiviral effect. To do so it would be 
needed to increase the concentrations range, that would allow us to also calculate the EC90, 
and to include cytotoxicity assays, that would allow to calculate the CC50 and CC90 values.  
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As discussed before, different cells can be used to replicate BKPyV. Nevertheless, different 
cells replicate differently and replicate BKPyV differently. As such, the cell number to be 
plated and the time of infection needed can be quite different when working with different 
cells. Knowing the virus replication cycle on the cell type to be used is of extreme importance 
prior to conducting an assay to evaluate a drug’s efficacy. One of the best in vitro models to 
study BKPyV infection is RPTEC. However, working with primary cells comes with its 
challenges, and many times cell lines are used instead. In this study we chose to work with 
RPTEC/TERT1, which as discussed before could have interfered with our results as the 
lentivirus vector used to immortalize this cell line contains SV40 sequences that can replicate 
in the presence of BKPyV. In future studies it should be considered the use of a different cell 
line like the one recently established by Zhao and Imperiale using a lentivirus vector that 
does not include SV40 sequences (101). Beyond the problems we found with the cell line 
chosen, when analyzing results obtained using cell lines caution must be taken as they do 
not always replicate primary cells. Because of this, especially when a strong effect is 
observed using cell lines, results should be confirmed on primary cells. 
PyVAN is attributed not to a primary infection with BKPyV but to a reactivation of a latent 
infection. As such, it would be interesting to study the drugs’ effect in these conditions. A 
chronic BKPyV infection model was already described on Vero cells (98). Using this model or 
similar ones, would allow us to test the drugs’ efficacy in conditions that are closer to what 
occurs in vivo. Additionally, they could also be used to evaluate whether previous exposure 
with the drug could be used for prophylaxis, preventing BKPyV reactivation. 
Overall, although only a moderate effect was found with these assays for both drugs tested, 
as this study was only a first approach on screening antiviral drugs against BKPyV, these 
results can help us to standardize future approaches on evaluating the anti-BKPyV effect of 
other potentially active drugs. As seen, to get a complete characterization of the drugs’ 
effect, the evaluation of the antiviral effect should be done in the different stages of viral 
replication to study their temporal effect. Additionally, it is essential to include cytotoxicity 
assays. These will give us an idea of their toxicity, and together with the results on efficacy 
will provide information on their selectivity. Another aspect that must always be taken in 
consideration is the cell type used and the adequacy of the time points chosen in relation to 
the replication of the virus on those specific cells.  
BKPyV reactivation in kidney transplant recipients still poses significant challenges. A better 
understanding of the virus and host factors that determine BKPyV reactivation and disease 
outcome could allow a risk stratification of kidney transplant recipients. Continuing the search 
and development for drugs with antiviral activity against BKPyV is still of great importance. 
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Defining a standardized high-throughput approach to evaluate antiviral activity would be 
useful to identify potential drugs with anti-BKPyV activity and compare results between 
studies. Some drugs have already shown a great anti-BKPyV effect in vitro and in some 
cases their use has already been reported in patients who developed PyVAN after kidney 
transplantation. Assessing their use in randomized controlled trials is essential so that strong 
conclusions about their efficacy can be made. Moreover, novel therapeutic approaches are 
emerging, such as immunotherapy using adoptive T cell transfer. Although their use to treat 
BKPyV-associated diseases is still in its early stages, further research in this area can bring 
some promising results. Finally, a vaccine targeting BKPyV that could efficiently prevent 
BKPyV reactivation in the first place would be a great step on preventing PyVAN 
development on kidney transplant recipients. 
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